X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs UNICHEM LAB - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA UNICHEM LAB SUN PHARMA/
UNICHEM LAB
 
P/E (TTM) x 38.0 -66.4 - View Chart
P/BV x 4.2 0.7 567.8% View Chart
Dividend Yield % 0.5 2.3 23.9%  

Financials

 SUN PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
UNICHEM LAB
Mar-18
SUN PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs842382 220.4%   
Low Rs572234 244.5%   
Sales per share (Unadj.) Rs131.6116.3 113.2%  
Earnings per share (Unadj.) Rs32.7-18.9 -172.8%  
Cash flow per share (Unadj.) Rs38.0-11.7 -323.4%  
Dividends per share (Unadj.) Rs3.505.00 70.0%  
Dividend yield (eoy) %0.51.6 30.5%  
Book value per share (Unadj.) Rs152.7381.0 40.1%  
Shares outstanding (eoy) m2,399.2670.34 3,410.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x5.42.6 202.9%   
Avg P/E ratio x21.6-16.3 -132.8%  
P/CF ratio (eoy) x18.6-26.2 -71.0%  
Price / Book Value ratio x4.60.8 572.8%  
Dividend payout %10.7-26.4 -40.5%   
Avg Mkt Cap Rs m1,696,87721,668 7,831.2%   
No. of employees `00017.52.3 768.2%   
Total wages/salary Rs m49,0232,006 2,443.3%   
Avg. sales/employee Rs Th18,028.33,587.8 502.5%   
Avg. wages/employee Rs Th2,798.8880.0 318.0%   
Avg. net profit/employee Rs Th4,479.5-583.7 -767.4%   
INCOME DATA
Net Sales Rs m315,7848,180 3,860.4%  
Other income Rs m6,232610 1,021.4%   
Total revenues Rs m322,0168,790 3,663.4%   
Gross profit Rs m100,893-1,320 -7,642.2%  
Depreciation Rs m12,648505 2,504.0%   
Interest Rs m3,99880 4,991.3%   
Profit before tax Rs m90,479-1,295 -6,985.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m99-2 -4,513.6%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,11633 36,252.8%   
Profit after tax Rs m78,462-1,331 -5,895.3%  
Gross profit margin %31.9-16.1 -198.0%  
Effective tax rate %13.4-2.6 -519.0%   
Net profit margin %24.8-16.3 -152.7%  
BALANCE SHEET DATA
Current assets Rs m329,53723,318 1,413.2%   
Current liabilities Rs m178,8704,635 3,859.0%   
Net working cap to sales %47.7228.4 20.9%  
Current ratio x1.85.0 36.6%  
Inventory Days Days79122 64.9%  
Debtors Days Days83121 68.5%  
Net fixed assets Rs m204,7668,163 2,508.4%   
Share capital Rs m2,399141 1,705.3%   
"Free" reserves Rs m363,99726,660 1,365.3%   
Net worth Rs m366,39726,801 1,367.1%   
Long term debt Rs m14,3613 435,175.8%   
Total assets Rs m614,10231,890 1,925.7%  
Interest coverage x23.6-15.2 -155.8%   
Debt to equity ratio x00 31,831.8%  
Sales to assets ratio x0.50.3 200.5%   
Return on assets %13.4-3.9 -342.3%  
Return on equity %21.4-5.0 -431.2%  
Return on capital %24.8-4.5 -546.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,1184,356 1,012.7%   
Fx outflow Rs m24,4840-   
Net fx Rs m19,6344,356 450.7%   
CASH FLOW
From Operations Rs m70,822-1,123 -6,304.3%  
From Investments Rs m-42,21616,487 -256.1%  
From Financial Activity Rs m-22,854-8,811 259.4%  
Net Cashflow Rs m6,1076,552 93.2%  

Share Holding

Indian Promoters % 63.7 50.1 127.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 15.1 34.0%  
FIIs % 23.0 3.0 766.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 31.7 26.2%  
Shareholders   133,026 20,176 659.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS